MULTIPLE AND DARATUMUMAB ABSTRACTS TO BE PRESENTED AT ASH ANNUAL MEETING

• Six ofatumumab abstracts to be presented at ASH • Five daratumumab abstracts to be presented at ASH

Copenhagen, Denmark; November 8, 2010 – A/S (OMX: GEN) announced today that multiple abstracts for ofatumumab and daratumumab will be presented at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition which will be held December 4-7, 2010 in Orlando, Florida. All abstracts are available on the ASH website at www.hematology.org.

Ofatumumab abstracts Abstract #921 Oral Presentation December 7 at 8:00 AM EST – Final Analysis From the International Trial of Single-Agent Ofatumumab in Patients with Fludarabine-Refractory CLL

Abstract #1795 Poster Presentation December 4 at 5:30-7:30PM EST – A Phase II Trial of Ofatumumab in Subjects with Waldenstrom’s Macroglobulinemia

Abstract #2464 Poster Presentation December 5 at 6:00-8:00 PM EST – Combination of Ofatumumab and in Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

Abstract #3575 Poster Presentation December 6 at 6:00-8:00PM EST – Complement Activation and Cytotoxicity in CLL Cells Treated with and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity

Abstract #3955 Poster Presentation December 6 at 6:00-8:00 PM EST – Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results from a Multicenter Phase II study

Abstract #3917 Poster Presentation December 6 at 6:00-8:00 PM EST – Ofatumumab, a Fully Targeting CD20, Demonstrates Activity Against and Potentiates the Anti- Tumor Activity of Chemotherapy Agents in -Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived from Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

Daratumumab abstracts Abstract #981 Oral Presentation December 7 at 8:00 AM EST – A Unique New Humanized Mouse Model for (MM): Opportunities for Studying MM in Its Natural Environment and for Preclinical Testing

Abstract #3058 Poster Presentation December 5 at 6:00-8:00 PM EST – In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab in the Treatment of Multiple Myeloma

Abstract #3013 Poster Presentation December 5 at 6:00-8:00 PM EST – Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Abstract #3059 Poster Presentation December 5 at 6:00-8:00 PM EST –Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Abstract #3030 Poster Presentation December 5 at 6:00-8:00 PM EST – Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and

Genmab A/S Tel: +45 7020 2728 Investor News no. 08 Bredgade 34 Fax: +45 7020 2729 Page 1/2 1260 Copenhagen K, Denmark www.genmab.com CVR no. 2102 3884

MULTIPLE OFATUMUMAB AND DARATUMUMAB ABSTRACTS TO BE PRESENTED AT ASH ANNUAL MEETING

About Ofatumumab Ofatumumab is a novel human monoclonal antibody. It targets a part of the CD20 molecule on B-cells encompassing an on the small and large loops.

About Daratumumab Daratumumab is a fully human IgG1,κ antibody in development to treat multiple myeloma (MM). Daratumumab targets the CD38 molecule which is very highly expressed on the surface of multiple myeloma cells. The antibody was selected from a large panel of antibodies based on its ability to bind to and kill multiple myeloma tumor cells.

About Genmab A/S Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit www.genmab.com.

Contact: Helle Husted, Vice President, Investor Relations T: +45 33 44 77 30; M: +45 25 27 47 13; E: [email protected]

This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-TF™; HuMax-Her2™; HuMax-Wnt™; HuMax-cMet™ and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Genmab A/S Tel: +45 7020 2728 Investor News no. 08 Bredgade 34 Fax: +45 7020 2729 Page 2/2 1260 Copenhagen K, Denmark www.genmab.com CVR no. 2102 3884